Armoda is a preparation of Armodafinil which is an indirect dopamine receptor agonist. Armodafinil is the R-enantiomer of Modafinil which is a 1:1 mixture of the R- and S-enantiomers. Armoda binds to the dopamine transporter and inhibits dopamine reuptake. As a result, Armoda increases neuronal activity in the hypothalamus, enhances activity in hypothalamic wakefulness center (TMN, tuberomammillary nucleus) within the hypothalamic sleep wake switch.
Armoda 250 Tablet
Adults Obstructive Sleep Apnea (OSA) & Narcolepsy 150 mg to 250 mg as a single dose in the morning. Shift Work Disorder (SWD) 150 mg as a single dose approximately 1 hour prior to the start of work shift. Children Safety and effectiveness in pediatric patients less than 17 years of age have not been established. Elderly In elderly patients, elimination of Armodafinil and its metabolites may be reduced as a consequence of aging. Therefore, consideration should be given to the use of lower doses and close monitoring in this population. Patients with hepatic impairment In patients with severe hepatic impairment, Armodafinil should be administered at a reduced dose. Patients with renal impairment There is inadequate information to determine safety and efficacy of dosing in patients with severe renal impairment.